When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Boston Scientific currently has an average brokerage re ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, it's pretty easy to find cutting-edge growth stocks with the he ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2695240 (State or other jurisdiction of incorporation or or ...

Boston Scientific Corporation (BSX) is gaining traction in the emerging markets. New regulatory approvals and accretive acquisitions bode well for long-term growth. The stock carries a Zacks Rank #2 (Buy) currently.Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In the last reported second quarter of 2024, despite geopolitical weaknesses, the emerging market registered sturdy growth, primarily banking on continued broad-based ...

2024 has been a great year for U.S. indices, with the benchmark S&P 500 posting new all-time highs 38 times so far. The rally has been primarily driven by the tech sector, focusing on artificial intelligence (AI). Several record-breaking stocks have seen triple-digit returns.However, the markets appear to have taken a summer breather in July. This raises the question of whether it’s time to buy the dip under the theory that record-breaking stocks have more upside ahead.While AI stocks have been the leader i ...

Core Insights - Boston Scientific Corporation (BSX) reported adjusted earnings per share (EPS) of 62 cents for Q2 2024, a 16.9% increase year-over-year, surpassing Zacks Consensus Estimate by 6.9% and exceeding its own guidance range of 57-59 cents [1] - The company achieved revenues of $4.12 billion in Q2 2024, reflecting a 14.5% year-over-year increase on a reported basis and 16.1% on an operational basis, exceeding Zacks Consensus Estimate by 2.5% [2] Revenue Performance - Q2 revenues rose 16.9% in the United States and 13.7% in the EMEA region, with Latin America and Canada seeing a 15.3% increase [3] - Emerging markets reported a revenue growth of 14.8% [3] Segment Analysis - Boston Scientific reorganized its operations into two segments: MedSurg and Cardiovascular, with Cardiovascular generating the most revenue [4] - Cardiovascular sales reached $2.05 billion, up 22% year-over-year, while MedSurg's Endoscopy segment generated $676 million, reflecting a 7.9% organic growth [4] Margin and Cost Analysis - Gross margin contracted by 143 basis points to 69.2%, with a 20% increase in the cost of products sold [5] - Adjusted operating margin expanded by 189 basis points to 24.6% [5] Guidance and Projections - The company raised its full-year net sales growth guidance to approximately 13.5-14.5% on a reported basis and 13-14% on an organic basis [7] - For Q3 2024, Boston Scientific estimates revenue growth of 13-15% and adjusted EPS in the range of 57-59 cents [8] Market Position and Outlook - The strong Q2 performance and raised guidance are expected to bolster investor confidence in Boston Scientific's stock [9] - The company continues to gain market share across all geographic regions despite macroeconomic challenges [9]

Key TakeawaysBoston Scientific's second-quarter earnings and revenue got a boost from high demand for its heart devices.Sales of cardiovascular products made up more than half of the company's revenue in the period.Boston Scientific raised its full-year adjusted earnings per share (EPS) and revenue growth estimates. Boston Scientific (BSX) posted an increase in second-quarter earnings and sales on the back of growing demand for its heart devices. The medical device maker recorded adjusted earnings per share ...

Financial Data and Key Metrics Changes - In Q2 2024, Boston Scientific reported consolidated revenue of $4.120 billion, representing a 14.5% growth compared to Q2 2023, with operational revenue growth of 16.1% after excluding a foreign exchange headwind of 160 basis points [22][24] - Adjusted EPS for Q2 2024 was $0.62, a 15.4% increase from 2023, exceeding the guidance range of $0.57 to $0.59 [9][22] - Adjusted operating margin for Q2 was 27.2%, expanding 40 basis points year-over-year, with expectations to raise the full-year adjusted operating margin expansion goal to 50 to 70 basis points [24][28] Business Line Data and Key Metrics Changes - The electrophysiology (EP) business saw organic sales growth of 125% in Q2, driven by the FARAPULSE PFA System [19] - Cardiology organic sales grew 22%, with interventional cardiology therapy sales increasing by 9% [16] - The urology business grew 9% organically, with strong performance in stone management and prosthetic urology [13] Market Data and Key Metrics Changes - U.S. operational sales grew 17% in Q2, with significant contributions from EP and med-surg businesses [11] - Europe experienced 16% operational growth, driven by double-digit growth in seven of eight business units [11] - Asia-Pacific grew 13% operationally, with high teens growth in China and double-digit growth in Japan [12] Company Strategy and Development Direction - The company aims to be the highest-performing med tech company in terms of sales and EPS growth, focusing on faster-growing markets and innovative product launches [32][34] - Boston Scientific is pursuing strategic acquisitions, including Silk Road Medical and SoundCath, to enhance its portfolio and market presence [26][63] - The company is committed to maintaining a strong product pipeline and clinical evidence generation to support its leadership in the electrophysiology market [20][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth through 2024 and into 2025, citing strong demand and market adoption for key products like FARAPULSE and WATCHMAN [31][34] - The company anticipates continued strong performance across its portfolio, with expectations for organic growth of 13% to 14% for the full year 2024 [10][27] - Management highlighted the importance of clinical evidence and product differentiation in maintaining competitive advantages in the market [40][44] Other Important Information - The company expects full-year 2024 free cash flow to exceed $2 billion, with a focus on strategic M&A and share repurchases [25][26] - Adjusted gross margin for Q2 was 70.4%, with expectations for improvement in the second half of the year [23][28] Q&A Session Summary Question: Sustainability of growth and guidance for 2024 - Management indicated that the strong performance in Q2 is not just a pull forward of revenues but reflects better demand and market adoption, with a goal to distinguish itself in revenue growth and EPS [31][34] Question: Future product rollouts and growth - Management emphasized the importance of a strong product pipeline and clinical evidence to support ongoing growth, particularly in the EP and WATCHMAN markets [37][38] Question: Durability of EP growth and competition - Management expressed confidence in the sustainability of EP growth, citing the safety and efficacy of FARAPULSE and the potential for continued market share gains [40][42] Question: Impact of mapping integrated catheter on growth - Management confirmed that the upcoming launch of the FARAWAVE catheter and FARAVIEW software is expected to drive adoption and enhance workflow efficiency in EP procedures [46][48] Question: Insights on TAVR and upcoming data - Management clarified that the data from the TAVR trial will be presented at the ACC meeting in 2025, emphasizing the significance of the trial's findings [70][74]

Boston Scientific (BSX) reported $4.12 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 14.5%. EPS of $0.62 for the same period compares to $0.53 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $4.02 billion, representing a surprise of +2.51%. The company delivered an EPS surprise of +6.90%, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

分组1 - Boston Scientific reported quarterly earnings of $0.62 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and up from $0.53 per share a year ago, representing an earnings surprise of 6.90% [1] - The company achieved revenues of $4.12 billion for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 2.51%, and an increase from $3.6 billion year-over-year [1] - Boston Scientific has consistently surpassed consensus EPS and revenue estimates over the last four quarters [1] 分组2 - The stock has gained approximately 35.9% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [2] - The current consensus EPS estimate for the upcoming quarter is $0.57 on revenues of $3.95 billion, and for the current fiscal year, it is $2.32 on revenues of $15.99 billion [4] - The Medical - Products industry is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [5]